MindMed Appoints Pharmaceutical Veteran Peter Bergethon, M.D. to Scientific Advisory Board

NEW YORK , June 17, 2021 /PRNewswire/ — MindMed (NASDAQ:MNMD) (NEO:MMED) (DE:MMQ) (the “Company”), a leading biotech company developing psychedelic-inspired therapies, has announced the addition of Dr. Peter Bergethon , a world-leading expert in neurology, digital medicine, and central nervous system (CNS) drug development to the Company’s Scientific Advisory Board. Dr. Bergethon is the Vice President and Head of Digital […]